Skip to main content
AN2 Therapeutics, Inc. logo

AN2 Therapeutics, Inc. — Investor Relations & Filings

Ticker · ANTX ISIN · US0373261058 US Manufacturing
Open in API
Filings indexed 340 across all filing types
Latest filing 2026-06-04 Regulatory Filings
Country US United States of America
Listing US ANTX

About AN2 Therapeutics, Inc.

https://www.an2therapeutics.com/

AN2 Therapeutics, Inc. is a biopharmaceutical company focused on discovering and developing treatments for rare, chronic, and serious infectious diseases with high unmet medical needs. The company utilizes its proprietary boron chemistry platform to create novel small molecule therapeutics. Its development pipeline includes boron-based compounds, such as its lead candidate epetraborole, which are being investigated as potential first-in-class or best-in-class therapies. The company's mission is to deliver high-impact drugs to improve global health outcomes, with potential applications extending to oncology.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 82% confidence The document is a Form 8-K Current Report filed under the Securities Exchange Act of 1934. It provides Regulation FD Disclosure and furnishes a press release with clinical trial results as Exhibit 99.1, along with other non-financial event disclosures. It is not a full annual or interim financial report, nor a management change or M&A announcement, nor a dividend or share transaction notice. This falls under miscellaneous regulatory announcements and is best classified as a Regulatory Filing (RNS).
2026-06-04 English
ARS - AN2 Therapeutics, Inc. (0001880438) (Filer)
Annual Report
2026-04-22 English
DEF 14A - AN2 Therapeutics, Inc. (0001880438) (Filer)
Proxy Solicitation & Information Statement
2026-04-22 English
424B3 - AN2 Therapeutics, Inc. (0001880438) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(3) related to the resale of common stock by selling securityholders. It includes detailed information about the offering, selling securityholders, plan of distribution, risk factors, and other related disclosures. The document is not a financial report, earnings release, or management discussion, but rather a capital markets filing related to securities registration and resale. This type of document fits the category of Capital/Financing Update (CAP), as it provides updates on the company's capital structure and securities offerings. The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief notice, confirming it is a substantive financing document rather than a mere announcement (RPA) or regulatory filing (RNS).
2026-04-20 English
S-3 - AN2 Therapeutics, Inc. (0001880438) (Filer)
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC under the Securities Act of 1933. It is a registration statement for the offering and sale of securities, including common stock, preferred stock, debt securities, warrants, and units. The document includes a base prospectus and prospectus supplements for various offerings. It is not a financial report, earnings release, management discussion, or any other report type but rather a capital markets filing related to securities issuance and registration. This fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and capital structure changes through securities registration and offerings.
2026-04-09 English
8-K - AN2 Therapeutics, Inc. (0001880438) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 9, 2026, reporting the entry into a new Open Market Sale Agreement with Jefferies LLC for an 'at the market' offering of up to $80 million of common stock. It also reports the termination of a previous sales agreement. The content focuses on capital raising activities and changes in financing agreements. There are no financial statements or earnings data presented, nor is this a full annual or quarterly report. The document is a current report on material events related to capital structure and financing. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is about 5,057 characters, sufficient to contain substantive information rather than a brief announcement or certification. Hence, the classification is CAP with high confidence.
2026-04-09 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.